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Sir,
We read with great interest a recently published article in your
journal titled ‘Capecitabine and bevacizumab as first-line treatment in
elderly patients with metastatic colorectal cancer’ (Feliu, 2010).
Initially, I would like to commend the authors of that article,
especially for their interest in finding effective treatment regimens for
the elderly, which are also associated with acceptable tolerance levels.
However, I would like to highlight certain data.
People aged 65 years and older have a cancer incidence 11 times
greater than that of younger individuals, and the risk of mortality
from malignancy is 16 times higher (http://seer.cancer.gov/csr/
1975_2000/). Demographic shifts are producing a very rapid growth
in at-risk populations, so that by 2030, 20% of the population will be
over 65 years. Unfortunately, oncologists are not sufficiently
prepared for this demographic shift, as their training focuses on
selecting the best therapeutic approaches for young and physically
healthy patients (Mandelblatt et al, 2000; Hurria et al, 2003). There
is, however, significant heterogeneity among elderly patients, even
among those with the same chronological ages. Such heterogeneity is
associated with different tolerance levels towards cancer treatments.
Oncologists need an assessment tool that will provide information
about the ‘functional age’ of older individuals, rather than the
‘chronological age’. An assessment tool named the ‘comprehensive
geriatric assessment’ (CGA) may help to identify elderly patients who
are most vulnerable to complications from cancer treatments. This
interdisciplinary assessment provides information about the patient’s
functional status, comorbidity, nutritional status, psychological status,
social support, cognitive status and other medications (Extermann
et al, 1998; Repetto et al,2 0 0 2 ;E x t e r m a n na n dH u r r i a ,2 0 0 7 ) .
Several cross-sectional studies have demonstrated an association
between the CGA and factors such as toxicity, morbidity and
mortality during cancer treatment in older patients (Extermann
et al, 2002; Audisio et al, 2005; Freyer et al, 2005; Maione et al,
2005; Ramesh et al, 2005).
In the field of geriatric oncology, the CGA can distinguish three
broad groups of elderly patients: (1) ‘fit’ patients, who can be
treated with chemotherapy in the same way as younger patients;
(2) ‘prefrail’ patients, for whom chemotherapy should be
administered with special schemes, reduced doses and haemato-
logical support factors; and (3) ‘frail’ patients, for whom the best
therapeutic option involves supportive care and nonspecific
palliative treatment (Balducci, 2007). However, the authors of the
article merely utilised three parameters to decide whether it was
possible to administer chemotherapy to the elderly: functional
status, as measured by the Lawton–Brody Scale and the Barthel
Scale; comorbidity, as measured by the Charlson Index; and the
researchers’ own subjective opinions. Recently, it has been
reported that low scores on the ‘Mini Nutritional Assessment’
(MNA) questionnaire, which is used to assess nutritional status,
and on the ‘Mini Mental State Examination’ (MMSE), which is
used to determine cognitive status, are associated with an
increased likelihood of elderly patients being unable to complete
chemotherapy. In addition, a low score on the MNA is associated
with an increased risk of mortality if chemotherapy is adminis-
tered to the elderly (Aaldriks et al, 2010). Such findings indicate
that there are sufficient functional status assessment options for
elderly patients with cancer.
Based on these data, we strongly advocate that the CGA be used
to evaluate elderly patients before the administration of any cancer
treatment. Although only a few authors have used specific models
of the CGA (Balducci, 2001; Ingram et al, 2002; Repetto et al, 2002;
Hurria et al, 2005; Overcash et al, 2006; Molina-Garrido and
Guille ´n-Ponce, 2010), any of these models could have been applied
to this study.
We also believe that the subjective data, though important in
subject areas with limited previous research, should be relegated to
the background, especially because there is an objective way to
evaluate elderly cancer patients: the CGA.
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